Novartis AG(NVS)Earnings, Financials & Key RatiosNovartis AG (NVS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the combination of a deteriorating current ratio of 0.85 and a high debt-to-equity ratio of 1.21 suggests significant structural risk as the company attempts to buy growth to offset patent cliffs.
Novartis AG (NVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Novartis AG (NVS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $1.99vs $2.11-5.7% | $13.1Bvs $13.4B-2.4% |
| Q1 2026 | Feb 4, 2026 | $2.03vs $1.99+2.0% | $13.3Bvs $13.7B-2.7% |
| Q4 2025 | Oct 28, 2025 | $2.25vs $2.26-0.4% | $14.4Bvs $13.6B+5.3% |
| Q3 2025 | Jul 17, 2025 | $2.42vs $2.38+1.7% | $14.3Bvs $13.9B+2.5% |
Recent stock market news and headlines for Novartis AG (NVS)
Novartis continues to favor in-licensing and bolt-on acquisitions. The Myricx Bio acquisition expands Novartis' ADC pipeline with novel NMTi payloads, but commercial impact is several years away. Avidity's del-brax and Ionis's pelacarsen, both late-stage assets, offer multibillion-dollar peak sales potential with pivotal data expected in the second half of the year.
NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.
The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis's oncology capabilities.
Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based biotechnology firm Myricx Bio in a deal expected to close in the second half of 2026.
Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.
Key metrics vs top competitors for Novartis AG (NVS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $157.03 | $299.63B | 21.84 | 5.97% | 25.64% | 31% | 2.56% | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $193.12 | $299.39B | 29.53 | 8.63% | 17.19% | 22.24% | — | |
| $49.64 | $220.59B | 14.10 | 6.43% | 37.2% | 66.36% | — | |
| $42.98 | $103.34B | 11.75 | 5.49% | 16.72% | 10.78% | — | |
| $53.32 | $107.23B | 7.16 | 4.11% | 19.19% | 31.48% | — |
Novartis AG (NVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Novartis AG (NVS) stock FAQ — growth, dividends, profitability & financials explained
Novartis AG (NVS) reported $56.05B in revenue for fiscal year 2025. This represents a 143% increase from $23.04B in 1998.
Novartis AG (NVS) grew revenue by 6.0% over the past year. This is steady growth.
Yes, Novartis AG (NVS) is profitable, generating $13.53B in net income for fiscal year 2025 (25.6% net margin).
Yes, Novartis AG (NVS) pays a dividend with a yield of 2.56%. This makes it attractive for income-focused investors.
Novartis AG (NVS) has a return on equity (ROE) of 31.0%. This is excellent, indicating efficient use of shareholder capital.
Novartis AG (NVS) generated $16.36B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
